DRMAW | Dermata Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0088 - 0.0110
52 Week Range	0.0088 - 0.0110
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,000
Average Volume	N/A
Shares Outstanding	200,366,181
Market Cap	2,755,036
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-08-13

Valuation
Profitability
Growth
Health
P/E Ratio	-0.01
Forward P/E Ratio	N/A
EPS	-2.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	DRMAW

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.

DRMAW's peers: EFTRW, NLSPW, DRMA, KTTAW, ZIVOW, GIPRW, BEATW, CINGW, EDBLW, ACONW

*Chart delayed

Analyzing fundamentals for DRMAW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see DRMAW Fundamentals page.

Watching at DRMAW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DRMAW Technicals page.